Article
Sanofi, GSK get nod for Phase 3 efficacy trial of their Covid -19 vaccine candidate in India
Rating:
0.0
Views:
163
Likes:
1
Library:
1
In this partnership Sanofi provides its recombinant antigen and GSK contributes its pandemic adjuvant, both established vaccine platforms that have proven successful against influenza.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value